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Original Article

Pretreatment neutrophil-to-lymphocyte ratio as an important
prognostic marker in stage III locally advanced non-small cell lung
cancer: confirmatory results from the PROCLAIM phase III clinical
trial
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Background: Neutrophil-to-lymphocyte ratio (NLR) is an important pretreatment marker of systemic

inflammation and tumor aggressiveness. Increased levels of this ratio have been associated with reduced
survival in several observational studies of lung cancer. However, supporting analyses from large clinical trial
data are lacking.
Methods: To validate the prognostic role of NLR, the current study evaluated data from a randomized phase

III study (PROCLAIM; clinicaltrial.gov ID: NCT00686959) of patients with stage IIIA/B, unresectable,
non-squamous, non-small cell lung cancer (NSCLC), originally comparing combination pemetrexedcisplatin chemoradiotherapy with etoposide-cisplatin chemoradiotherapy. Adjusted hazard ratios (aHR) and
95% confidence intervals (CI) for survival were estimated using a Cox proportional hazards model. Models
were adjusted for age, race, sex, stage, treatment, and body mass index (BMI). Patients were followed for a
median of 24 months.
Results: Increased NLR levels at baseline were associated with reduced overall (P Trend <0.0001) and

progression-free survival (P Trend <0.005). A similar but decreasing linear trend was not observed for
lymphocytes count alone.
Conclusions: These findings provide substantiating evidence that NLR, which is routinely available from

standard blood testing of patients diagnosed with NSCLC, is an important inflammation-based prognostic
marker for survival among patients with locally advanced disease undergoing chemoradiation. Future
research will benefit by assessing the prognostic potential of NLR in the context of genetic mutations and
molecular markers.
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Introduction
Lung cancer is the leading cause of cancer-related mortality
in the United States (1). Non-small cell lung cancer
(NSCLC) is the most common variant, accounting for
approximately 85% of cases. One third of patients newly
diagnosed with NSCLC present with locally advanced, nonmetastatic malignancy (2,3). Recent treatment advances
include the use of novel immune checkpoint inhibitors
(ICI) (4). Nonetheless, the prognosis of patients diagnosed
with stage IIIA and IIIB NSCLC remains poor, with fiveyear survival rates of 14% and 5%, respectively (5). Locally
advanced NSCLC is a challenging disease with a paucity of
information to guide treatment decisions. A need remains
to independently validate non-invasive prognostic markers
for this disease, especially in the context of a sufficiently
powered randomized clinical trial (6).
In 1836, inflammation was first associated with cancer
by Rudolf Virchow, when his microscopic analysis of
tumors showed gross infiltration of lymphocytes and
macrophages (7). In recent years, the importance of
inflammation in carcinogenesis and tumorigenesis has
become increasingly established. The presence of chronic
inflammatory states in the tumor microenvironment
has been implicated in every step of carcinogenesis by
promoting oncogenic mutations, accelerating neoplastic
proliferation, and encouraging seeding and metastasis (8).
Localization of inflammatory activity directly exposes
native tissues and cells to reactive oxygen species (ROS),
which activates oncogenes and introduces deleterious
mutations to essential tumor suppressor genes (9). Having
undergone malignant transformation, these cells stimulate
localized inflammation by the secretion and attraction of
pro-inflammatory factors IL-1, IL-6, IL-8, and TNFalpha, which induce further mutation and oncogenesis (10).
Specific to NSCLC, loss-of-function mutations to the
PTEN tumor suppressor gene results in upregulated
HIF-1 and HIF-1-dependent transcription of chemokine
receptor gene CXCR4, which plays a critical role in
malignant cell survival and proliferation within the tumor
microenvironment (11).
Changes in neutrophil and/or lymphocyte counts in
peripheral blood are important surrogate markers of
systemic inflammation and cancer-targeted immune reaction.
Polymorphonuclear neutrophils (PMN) are leukocytes that
are produced in response to systemic inflammation and
facilitates oncogenesis by directly and indirectly inducing
tumor proliferation and metastasis. PMN are activated in
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response to hematopoietic cytokine overactivation, which
indicate hyper-inflammatory states that contribute to
tumor angiogenesis and metastasis seen in more aggressive
cancers (12). Once activated, PMN are attracted to the
tumor microenvironment by IL-8 and IL-17, both of
which are produced in abundance owing to K-RAS and
other oncogenic mutations on malignant cells (13). Once
in the tumor microenvironment, PMN further induce prooncogenic mutations through over-production of ROS and
promote vessel proliferation involving various angiogenic
factors. PMN also promote detachment and intravasation
of malignant cells into vasculature through endothelialmesenchymal transition (14). By contrast, increased
lymphocyte counts have been implicated in suppression
of tumor growth and activation of pro-apoptotic activity
within the tumor with CD8+ T-lymphocytes (CTL) directly
induce apoptosis of tumor cells; depressed lymphocyte
counts in NSCLC patients has been directly associated
with decreased survival. PMN and CTL populations are
directly impacted by systemic inflammatory states. IL-1, a
leukocyte activation factor associated with inflammation,
directly contributes to higher circulating PMN counts
(neutrophilia), attracts activated PMN to regions of
localized inflammation, and reduces lymphocyte counts
(lymphopenia) (15-18).
Inflammation within the premalignant microenvironment
also incites genetic mutations underlying tumor growth
through intrinsic and extrinsic pathways (19,20). In prior
analyses, systemic inflammatory markers have demonstrated
both prognostic and predictive value in cancer patients.
Neutrophil-to-lymphocyte ratio (NLR) is a method of
quantifying inflammatory and immune status. NLR has
been associated with survival outcomes for several types
of solid tumors (21-26). Higher NLR levels have been
linked with more aggressive cancer, decreased efficacy of
antineoplastic therapy and poorer clinical outcomes (27,28).
Although NLR has been well-studied previously, in both
NSCLC as well as other malignancies, this marker remains
to be independently validated in the context of a large
clinical trial with systematic data collection (29).
The objective of the current analysis was to test the
hypothesis that increases in NLR are associated with
decreased overall survival (OS) and progression-free survival
(PFS) in locally advanced NSCLC using a prospective
randomized study dataset.
We present the following article in accordance with the
REMARK reporting checklist (available at https://dx.doi.
org/10.21037/jtd-21-1018).
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Methods
Study design
Data for the current analysis was obtained from the
PROCLAIM trial (Eli Lilly), a 5-year randomized study
comparing cisplatin-pemetrexed (PEM) and cisplatinetoposide (ETO) with concurrent radiation in patients with
stage IIIA/B, unresectable, non-squamous, NSCLC (30).
Participants were deemed eligible if they were ≥18 years old
and had an Eastern Cooperative Oncology Group (ECOG)
Performance Status (PS) of 0/1. Evaluable disease was
assessed by computed tomography (CT) imaging and with
response evaluation criteria in solid tumors (RECIST) (31).
Radiation doses targeted to the thoracic region ranged from
60 to 66 Gy (2 Gy/fraction daily, 5 days per week) and were
delivered concurrently with chemotherapy starting with
day 1 of infusion. The data used in our analysis included
pre-treatment blood counts for neutrophils, platelets, and
lymphocytes, reported as International System of Units (SI).
Among the 598 randomly assigned patients in PROCLAIM,
approximately 2% were excluded from the analysis (n=7 had
incomplete staging information, demographic details (race,
sex), or RT start or key laboratory dates, or lacked follow-up
times; n=5 did meet entry criteria and/or physician decision).
Therefore, 586 were included in the current study.
The PROCLAIM clinical trial followed the International
Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use (ICH) Good Clinical
Practice (GCP) guidelines in effect at the time of the
study (32). These guidelines set ethical and scientific
quality standards for conducting, designing, recording, and
reporting clinical trials. Additionally, our study adhered
to the Reporting Recommendations for Tumor Marker
Studies (REMARK) (6). Per protocol, the PROCLAIM
study was designed as a superiority trial with 80% power
to detect stated effects at the α=0.05 level of statistical
significance; post-hoc analyses and power were not specified
in the PROCLAIM study.
The study was conducted in accordance with the
Declaration of Helsinki (as revised in 2013). This was an
analysis of de-identified data from the PROCLAIM study
(Eli Lilly). No patients were involved or contacted for the
current manuscript and the analysis was considered IRB
exempt by Code of Federal Regulations 45 part 46.101(b).

categorical variables, while continuous variables were
reported as medians and interquartile ranges (IQR). NLR
values were logarithmically transformed (base e) before
performing statistical analysis to minimize heteroscedasticity
and skewness of the underlying distribution.
Adjusted hazard ratios (aHRs) and 95% confidence
intervals (CI) for survival were estimated using a Cox
(proportional hazards) regression model. HRs denote
the relative instantaneous incidence of mortality between
comparisons groups and are used to estimate relative risk. In
a Cox regression analysis, the dependent variable represents
the logarithm of the incidence rate, given varying lengths of
time for follow-up. Independent variables are used to gauge
the risk (or hazard) of experiencing an event at a given point
in time, conditional on that one has not experienced the
event before that time.
Models were adjusted for age, race, sex, stage, treatment,
and body mass index (BMI), with the latter being a
predisposing factor for inflammation. The parallel hazards
assumption was not violated in our main Cox regression
models (33). Product-limit estimates and corresponding
Kaplan-Meier curves were used to visualize survival times
over all observations.
NLR values were determined to be approximately
symmetrical after logarithmic transformation (homogeneous
risk within categories) and stratified by quartiles
(Q1–Q4) for the survival analyses. Neutrophil and lymphocyte
values were similarly transformed. Values presented in the
text and tables were back transformed to their original nonlogarithmic values to aid clinical interpretation of the results.
P values for linear trend across risk quartiles were computed
using a likelihood ratio test.
OS was defined as the time from baseline (date of random
assignment) to any cause of death. PFS was similarly defined
in terms of the first date of documented progressive disease or
death. OS time was censored at the date the patient was last
known to be alive at the time of data freeze (end of 2015), and
the date of the last progression-free disease assessment, death,
or subsequent systemic anticancer therapy in the case of PFS.
Numbers were rounded using the Goldilocks (EfronWhittemore) method (34). P values <0.05 were defined as
statistically significant. SAS statistical software (version 9.4,
SAS Institute Inc., Cary, NC, USA) was used for all analyses.
Results

Statistical analysis

Patient characteristics

Frequencies and percentages were used to summarize

The median patient age of the 586 study participants
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Table 1 Overall and progression-free survival for indicated characteristics (N=586)
Characteristic

N [%]

Overall Survival
†

Progression-Free Survival
†

HR (95% CI)

P

HR (95% CI)†

P†

Age (y)

59 [14]*

<50

110 [19]

1.0 Referent

–

1.0 Referent

–

50–59

207 [35]

0.87 (0.64–1.2)

0.37

0.73 (0.55–.96)

0.027

60–69

198 [34]

0.99 (0.73–1.3)

0.93

0.82 (0.62–1.1)

0.16

71 [12]

1.4 (0.97–2.1)

0.072

1.2 (0.85–1.7)

0.29

70+
2

BMI (kg/m )

25 [6]*

Underweight (<18.5)

30 [5]

1.0 Referent

–

1.0 Referent

–

Normal (18.5 to <25)

272 [46]

1.0 (0.61–1.7)

0.95

0.94 (0.59–1.5)

0.79

Overweight (25 to <30)

201 [34]

1.0 (0.62–1.8)

0.88

0.88 (0.55–1.4)

0.58

Obese (30+)

83 [14]

0.97 (0.55–1.7)

0.89

0.89 (0.53–1.5)

0.89

White

416 [71]

1.0 Referent

–

1.0 Referent

–

Black

27 [5]

1.1 (0.67–1.8)

0.70

1.2 (0.73–1.9)

0.49

122 [21]

0.86 (0.65–1.1)

0.26

1.3 (1.01–1.6)

0.044

21 [4]

0.90 (0.48–1.7)

0.74

0.98 (0.54–1.8)

0.94

Race

East Asian
Other
Sex

0.0037

0.025

Male

349 [60]

1.0 Referent

1.0 Referent

Female

237 [40]

0.72 (0.58–.90)

0.79 (0.65–.97)

Smoker

0.087

Never

91 [16]

1.0 Referent

–

1.0 Referent

Former

351 [60]

1.2 (0.89–1.7)

0.22

0.76 (0.57–1.01)

Current

144 [25]

1.3 (0.94–1.9)

0.11

0.76 (0.55–1.04)

Stage

0.0047

IIIA

279 [48]

1.0 Referent

–

1.0 Referent

IIIB

307 [52]

1.3 (1.01–1.5)

0.037

1.3 (1.09–1.6)

Treatment

0.17

ETO

287 [49]

1.0 Referent

–

1.0 Referent

PEM

299 [51]

1.0 (0.81–1.2)

0.97

0.87 (0.72–1.1)

†

, Wald test. *, data presented as Median [IQR]; BMI, body mass index; CI, confidence interval; ETO, cisplatin + etoposide; kg, Kilogram;
HR, unadjusted hazard ratio; m, Meter; PEM, cisplatin + pemetrexed.

was 59 years (IQR 14) (Table 1). Approximately 60%
were male and slightly over 50% presented with stage
IIIB disease. Adenocarcinomas were the predominant
histologic type (>75%). The main race was Caucasian
(71%). On average, patients had a BMI of 25 (IQR 6)

© Journal of Thoracic Disease. All rights reserved.

and 60% were former smokers. There were 299 patients
who received PEM (51%), and 287 (49%) who received
ETO as part of their treatment regimens. Female patients
had better overall survival outcomes than male patients
(OS: HR =0.72; PFS: HR =0.79). OS (P=0.037) and PFS

J Thorac Dis 2021;13(10):5617-5626 | https://dx.doi.org/10.21037/jtd-21-1018

Journal of Thoracic Disease, Vol 13, No 10 October 2021

5621

Table 2 Overall and progression-free survival by inflammatory markers
Overall survival
Inflammatory marker

Progression-free survival
¥

Univariable

Multivariable

Multivariable¥

Univariable

HR (95% CI)

P†

aHR (95% CI)

P†

HR (95% CI)

P†

aHR (95% CI)

P†

1.0 Referent

–

1.0 Referent

–

1.0 Referent

–

1.0 Referent

–

Q2 (>1.5–1.9)

0.72 (0.53–0.96)

0.026

0.71 (0.53–.95)

0.023

0.80 (0.61–1.1)

0.10

0.78 (0.59–1.03)

0.075

Q3 (>1.9–2.4)

0.81 (0.61–1.1)

0.16

0.77 (0.58–1.03)

0.081

0.97 (0.74–1.3)

0.79

0.92 (0.69–1.2)

0.53

Q4 (>2.4)

0.78 (0.59–1.1)

0.10

0.79 (0.59–1.1)

0.13

0.74 (0.56–.97)

0.029

0.74 (0.56–.97)

0.031

0.19

–

0.18

–

0.097

–

0.089

–

Q1 (≤4.4)

1.0 Referent

–

1.0 Referent

–

1.0 Referent

–

1.0 Referent

–

Q2 (>4.4–5.5)

1.1 (1.3–2.4)

0.0002

1.2 (0.84–1.6)

0.36

1.1 (0.80–1.4)

0.73

1.0 (0.79–1.4)

0.78

Q3 (>5.5–7.1)

1.2 (0.88–1.6)

0.26

1.6 (1.2–2.2)

0.0029

1.2 (0.91–1.6)

0.19

1.3 (0.96–1.7)

0.099

Q4 (>7.1)

1.6 (1.2–2.2)

0.0021

1.8 (1.3–2.5)

0.0004

1.1 (0.84–1.5)

0.45

1.2 (0.87–1.6)

0.31

<0.0001

–

<0.0001

–

0.30

–

0.17

–

Q1 (≤2.1)

1.0 Referent

–

1.0 Referent

–

1.0 Referent

–

1.0 Referent

–

Q2 (>2.1–3.0)

1.1 (0.81–1.5)

0.52

1.1 (0.78–1.5)

0.67

0.85 (0.64–1.1)

0.26

0.82 (0.62–1.1)

0.18

Q3 (>3.0–4.1)

1.5 (1.1–2.0)

0.012

1.5 (1.1–2.0)

0.015

1.2 (0.94–1.6)

0.14

1.3 (0.97–1.7)

0.082

Q4 (>4.1)

2.0 (1.5–2.7)

<0.0001

1.9 (1.4–2.6)

<0.0001

1.2 (0.94–1.6)

0.12

1.3 (0.998–1.8)

0.052

<0.0001

–

<0.0001

–

0.020

–

0.050

–

Lymphocyte¶Ʌ
Q1 (≤1.5)

§
Trend

P

¶Ʌ

Neutrophil

§
Trend

P

¶Ʌ

NLR

§
Trend

P
¥

, adjusted for age (continuous), BMI (continuous), sex (male, female), race (white, black, East Asian, other), stage (IIIA, IIIB), treatment
(cisplatin + etoposide, cisplatin + pemetrexed); †, Wald test; ¶, back-transformed from logarithmic values; Ʌ, pretreatment (baseline); §,
Likelihood ratio test for trend. aHR, adjusted hazard ratio; BMI, body mass index. CI, confidence interval. ETO, cisplatin + etoposide. HR,
unadjusted hazard ratio. NLR, neutrophil-lymphocyte ratio. PEM, cisplatin + pemetrexed. PLR, platelet-lymphocyte ratio. Q, quartile.

(P=0.0047) times were significantly shorter among patients
with stage IIIB vs. IIIA disease. There was no significant
difference in OS between the two treatment regimens
(HR =1.0, P=0.97). The median baseline neutrophil and
lymphocyte counts were 5.5 (IQR 2.7) and 1.9 (IQR 0.91),
respectively (not shown in Table 1). Patients were followed
for a median of 24 months (IQR 22).
Survival outcomes
No significant association was demonstrated between OS
and baseline lymphocyte count, although lymphocyte counts
above 2.4 were significantly associated with better PFS than
a lymphocyte counts less than or equal to 1.5 (HR =0.74,
P=0.029). No significant association or linear trend was

© Journal of Thoracic Disease. All rights reserved.

noted between lymphocyte counts and OS or PFS (Table 2).
Increased baseline neutrophil counts were significantly
associated with worse OS, with patients in the Q4 range
(>7.1) having a HR of 1.6 (P=0.0021) and aHR of 1.8
(P=0.0004) compared with referents in the Q1 range (≤4.4).
No significant association was noted for PFS. Increasing
baseline neutrophil counts showed a significant trend for
worse OS, before and after adjusting for demographic
characteristics i.e., age, BMI, cancer type, gender (PTrend
<0.0001); however, no such association was noted for PFS.
At baseline, a higher NLR was associated with poorer
OS. The five-year OS rate for patients with NLR ≤2.1 was
39%, while for patients with NLR >4.1, the rate was 20%,
with a significant trend towards decreased OS as NLR
increased (Table 3). Higher baseline NLR was associated
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Table 3 Overall and progression-free survival by indicated year following baseline
Overall survival, percentage (95% CI)

Inflammatory marker

Progression-free survival, percentage (95% CI)

1-Year

3-Year

5-Year

1-Year

3-Year

5-Year

Q1 (≤2.1)

0.80 (0.72–0.85)

0.50 (0.41–0.59)

0.39 (0.28–0.49)

0.45 (0.36–0.54)

0.17 (0.11–0.26)

0.13 (0.06–0.22)

Q2 (>2.1-3.0)

0.82 (0.74–0.87)

0.45 (0.36–0.53)

0.38 (0.29–0.47)

0.53 (0.44–0.62)

0.24 (0.16–0.32)

0.19 (0.12–0.28)

Q3 (>3.0-4.1)

0.74 (0.66–0.80)

0.36 (0.28–0.45)

0.24 (0.16–0.33)

0.41 (0.32–0.50)

0.10 (0.05–0.17)

0.09 (0.04–0.15)

Q4 (>4.1)

0.69 (0.61–0.76)

0.24 (0.16–0.31)

0.20 (0.13–0.29)

0.35 (0.27–0.44)

0.14 (0.08–0.22)

0.12 (0.06–0.20)

NLR¶

¶

, back-transformed from logarithmic values. CI, confidence interval; Q, quartile.

A
1.0
0.8
0.6

Q1

0.4

Q2

0.2

Progression-free survival
By log (neutrophil to lymphocyte ratio)
1.0

aHR (Q4 vs.Q1)= 1.9 (95% CI: 1.4−2.6), P<0.0001

Survival probability

Survival probability

B

Overall survival
By log (neutrophil to lymphocyte ratio)

Q3
Q4

0.0

aHR (Q4 vs.Q1)= 1.3 (95% CI: 0.998−1.8), P<0.052

0.8
0.6
0.4
0.2

Q1

20

40
Months

60

Q4
Q3

0.0
0

Q2

0

20

40
Months

60

Figure 1 Kaplan-Meier plots for overall survival (A) and progression-free survival (B) by quartile groups (Q1-Q4).

with trends towards shorter PFS. Patients with baseline
NLR ≤2.1 had PFS rates of 45% and 17% at 1 and 3 years,
respectively; conversely, patients with NLR >4.1 had PFS of
35% and 14% at 1 and 3 years, respectively. Kaplan Meier
curves for OS and PFS are shown in Figure 1A,1B.
Discussion
Systemic inflammation has a pivotal role in the progression
of various cancer subtypes including NSCLC by promoting
tumor angiogenesis, proliferation and ultimately metastasis.
This chronic condition also affects tumor response to
cancer treatment, including radiation and chemotherapy.
NLR, which is the ratio of the circulating neutrophil
and lymphocyte, is an important marker for systemic
inflammation. The results of the current study further
highlight that this inflammation-based prognostic score is a
reliable pretreatment marker for survival outcomes among
patients with newly diagnosed stage III NSCLC undergoing
chemo-radiation. Our analysis of a large phase III clinical

© Journal of Thoracic Disease. All rights reserved.

trial dataset supports the findings of several smaller, singlecenter, and/or less-extensive studies, and sets the stage for
exploring the prognostic role of NLR in the era of cancer
immunotherapy (35).
Our analysis is in alignment with the meta-analysis
showing increased baseline NLR is associated with worse
survival in NSCLC (36). However, in comparison with
the published meta-analysis which has several limitations
because of the underlying heterogeneity in the published
articles, along with small sample size of individual studies,
the current analysis is from a large, randomized dataset
supporting the role of baseline NLR values as a significant
prognostic marker for locally advanced NSCLC.
Individual lymphocyte and neutrophil counts were
associated separately with OS and PFS in our analysis, with
the magnitude of the reciprocal effect of lymphocyte counts
being considerably smaller than that NLR. While the
aHRs for survival were similar for neutrophils counts alone
and NLR, we posit that NLR may be a more clinically
relevant prognostic marker when applied to individual
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patients. For example, exogenous corticosteroid use causes
iatrogenic neutrophilia by directly inhibiting endovascular
L-selectin synthesis (37-42). Steroids directly inhibit
inflammatory processes, and thus there would not be an
associated decrease in circulating lymphocytes typically
seen in systemic inflammation (43,44). Correspondingly,
NLR in patients treated with corticosteroids would be less
pronounced.
As utilization of ICIs become more common in the
treatment of NSCLC, the value of systemic inflammation
needs to be explored further. This is particularly relevant,
given that less than 25% of patients positively respond to
ICIs as monotherapy for NSCLC (45). NLR also may play
a role in the selection of patients to enroll in future clinical
trials of these agents. There have been conflicting reports in
defining the prognostic role of NLR in patients treated with
ICIs. A recent systematic review and network meta-analysis
of 3,024 patients treated with ICIs reported that high pretreatment NLR is associated with poor PFS and OS (46). In
stage III unresectable NSCLC, consolidative durvalumab
for one year has become the standard of care based on the
PACIFIC trial (47).
Radiation therapy is known to cause lymphopenia more
pronounced than chemotherapy alone. For NSCLC,
expression of PD-L1 is an acceptable marker to predict
response rate to these agents. At present, in the postchemoradiation setting, whether NLR will add to value in
predicting outcome is unknown. Further studies are needed
to investigate the role of the immune environment and high
levels of NLR caused by chemo-radiation in predicting
response to consolidative durvalumab.
To the best of our knowledge, the current study is the
first large-scale analysis examining the prognostic survival
potential of pretreatment NLR in patients diagnosed
with locally advanced, stage IIIA/B NSCLC utilizing a
prospective clinical trial dataset. Additionally, only nonsquamous cell cancers were included, eliminating variability
between different histologies.
Biomarker studies often yield inconsistent conclusions
owing to poor study design, methodological problems, nonstandardized assays, misleading statistical analyses, and a
general lack of rigor and reproducibility (6). Finding reliable
and valid prognostic markers that predict clinical outcomes
and aid in the selection of a targeted treatment plan remains
paramount to the field oncology. Previously published
reports of NLR as a prognostic marker for NSCLC either
had a small sample size (48-50) or were retrospective in
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nature (51,52), included patients with non-stage III disease
(27,53-57), or surgical series and/or analyzed outcomes other
than mortality. In contrast, our study analyzed data obtained
from a phase III clinical trial of stage IIIA/B NSCLC
patients and exclusively considered pretreatment NLR and
survival outcomes. Additionally, we avoided arbitrary and
data-dependent cutoff points by defining comparison groups
based on their exact quartile values.
Certain limitations should be noted when considering
our results. The NLR was not the a priori aim of the initial
trial, which also preceded the usage of ICIs that are now
critical tools for achieving favorable response in NSCLC.
Clinical trials also may not be reflective of the general
population, owing to restrictive inclusion and exclusion
criteria (41). Information on competing causes of deaths
was not available in this analysis. Consequently, all causes
of death were independently censored, which may have
inflated the proportion of deaths attributable to lung cancer
in our Cox-proportional models (58). Nonetheless, the
effect of competing risk in advanced stage lung cancer is
nominal in comparison with other less invasive tumors.
Overall, pre-treatment NLR ratio is an important
prognostic marker for patients presenting with locally advanced
non-squamous NSCLC who underwent definitive chemoradiation. Future large-scale studies are needed to investigate
the value of post-chemoradiation and pre-durvalumab NLR,
or other systemic immune-inflammation indexes, in stage III
NSCLC. Targeted therapies directed at driver gene mutations
(e.g., anti-EGFR, anti-VEGF, anti-ALK, MET, and BRAF)
also are promising therapeutic agents in the context of NLR
and NSCLC survival outcomes. Carefully examining the
effect modification of NLR status and the use of targeted
therapies such as Afatinib, Alectinib, Cabozantinib, Ceritinib,
E Crizotinib, Dabrafenib/Trametinib, Gefitinib, Osimertinib,
Rlotinib, merits further consideration (59).
Conclusions
NSCLC is a complex disease, and few validated markers
are currently available for predicting mortality outcomes of
this cancer. In contrast to exploratory retrospective studies,
our hypothesis-driven analysis provides confirmatory
evidence that higher pre-treatment NLR is a consistent
indicator of decreased OS and PFS in stage IIIA/B NSCLC.
Future research will benefit from exploring the increased
prognostic value of NLR in the setting of various genetic
mutations and molecular markers.
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